|Seeking Horses with Cushing’s Disease for Research Study|
(December 2, 2008 Stillwater, OK) – In collaboration with OSU, Elanco Animal Health, a Division of Eli Lilly and Company, is seeking horses afflicted with Equine Cushing’s Disease also known as Pituitary Pars Intermedia Dysfunction (ECD/PPID) to participate in a research study. OSU is recruiting cases of ECD/PPID to document the efficacy and safety of pergolide in support of FDA approval. An FDA approved pergolide product for horses afflicted with ECD will assure the access to and the uniformity and quality of a pergolide therapy for horses in the United States.
Horses nearing 15 to 20 years of age or older that have not shed out well in the spring for the past one or two years are possibly developing ECD/PPID. Additional signs can include increased water consumption and urination, loss of muscle over the top line, and possibly concurrent development of abnormal fat deposits, such as crested neck and/or a bulge of fat over each eye. Another sign is unexplained laminitis (founder) and recurrent or chronic infections. If one or more of these signs is noted in an aged horse, then the horse may be a candidate for the study. To be included in this study, horses should not have been treated with medications or dietary supplements recommended for ECD/PPID within 60 days of study pergolide treatment initiation.